Effect of castalagin against HSV-1 infection in newborn mice

Nat Prod Res. 2023 Nov-Dec;37(24):4156-4161. doi: 10.1080/14786419.2023.2173191. Epub 2023 Jan 30.

Abstract

We tested in vivo anti-herpetic effect of castalagin, an ellagitannin compound, extracted from pedunculate oak (Quercus robur). Previous investigations found that castalagin possesses a strong inhibitory effect in vitro against HSV-1/2 equal to acyclovir (ACV). It is also effective against ACV-resistant mutants and shows a synergistic effect with ACV. We study castalagin's activity towards HSV-1 infection in newborn mice. Acute toxicity determination in mice showed LD50 value of 295 mg/kg. Prolonged toxicity was also constructed. Castalagin manifested a marked activity against HSV-1 (LD90/0.02 ml) administered in 7-day course at 0.02 ml s.c. doses of 7.5 or 10 mg/kg (PI 57-58%). ACV course demonstrated a marked activity at 20 mg/kg. The selectivity ratio LD50/ED50 (295/7.5) could be accepted as ≥ 33.

Keywords: Herpes simplex virus type 1; castalagin; mice; toxicology.

MeSH terms

  • Acyclovir / pharmacology
  • Animals
  • Animals, Newborn
  • Antiviral Agents / pharmacology
  • Herpes Simplex* / drug therapy
  • Herpesvirus 1, Human*
  • Herpesvirus 2, Human
  • Hydrolyzable Tannins / pharmacology
  • Mice

Substances

  • vescalagin
  • Hydrolyzable Tannins
  • Antiviral Agents
  • Acyclovir